Genco Merve, Genco Mehmet, Vural Fisun, Koç Nermin
Department of Obstetrics and Gynecology, Haydarpaşa Numune Training and Research Hospital, Istanbul 34668, Turkey.
Department of Pathology, Haydarpaşa Numune Training and Research Hospital, Istanbul 34668, Turkey.
J Clin Med. 2025 May 11;14(10):3334. doi: 10.3390/jcm14103334.
The aim of the present study was to explore the histopathological effects and tissue Vascular Endothelial Growth Factor (VEGF) levels of filgrastim and hyaluronic acid treatment in a rat model with experimentally induced Asherman syndrome. In this study, 26 female Sprague Dawley rats were used. First, a rat model of Asherman syndrome was established in two rats, and the remaining rats were randomly divided into three groups. A total of 0.1 mL trichloroacetic acid was applied to the right uterine horns of all groups to induce adhesion formation.Group I received no treatment, Group II received intrauterine hyaluronic acid treatment (0.01), Group III received subcutaneous Filgrastim treatment (50 μg/kg/day), and Group IV received both intrauterine hyaluronic acid and subcutaneous Filgrastim treatment. Histopathological analysis of uterine horns in the rats with and without Asherman syndrome, inflammation, glandular count, and fibrosis levels were examined. Tissue VEGF levels were investigated immunohistochemically. Hyaluronic acid treatment resulted in an increase only in uterine lumen diameter and VEGF levels, while Filgrastim treatment led to an increase in uterine wall diameter, lumen diameter, gland count, and VEGF levels, as well as a decrease in fibrosis and inflammation scores. Combined treatment with filgrastim and hyaluronic acid showed an increase in lumen diameter, gland count, and VEGF levels, along with a decrease in inflammation and fibrosis scores ( < 0.05). Filgrastim treatment resulted in better effects for Asherman syndrome compared to hyaluronic acid treatment. There were no beneficial effects seen with the combined therapy. Filgrastim treatment resulted in better outcomes for Asherman syndrome compared to hyaluronic acid treatment. The combined therapy did not show additional benefits beyond what was achieved with Filgrastim treatment alone.
本研究的目的是探讨非格司亭和透明质酸治疗对实验性诱导的阿谢曼综合征大鼠模型的组织病理学影响及组织血管内皮生长因子（VEGF）水平。在本研究中，使用了26只雌性斯普拉格-道利大鼠。首先，在两只大鼠中建立阿谢曼综合征大鼠模型，其余大鼠随机分为三组。对所有组的右子宫角应用总共0.1 mL三氯乙酸以诱导粘连形成。第一组不接受治疗，第二组接受子宫内透明质酸治疗（0.01），第三组接受皮下非格司亭治疗（50μg/kg/天），第四组接受子宫内透明质酸和皮下非格司亭联合治疗。检查有无阿谢曼综合征大鼠的子宫角组织病理学分析、炎症、腺体计数和纤维化水平。采用免疫组织化学方法研究组织VEGF水平。透明质酸治疗仅导致子宫腔直径和VEGF水平增加，而非格司亭治疗导致子宫壁直径、腔直径、腺体计数和VEGF水平增加，以及纤维化和炎症评分降低。非格司亭和透明质酸联合治疗显示腔直径、腺体计数和VEGF水平增加，同时炎症和纤维化评分降低（<0.05）。与透明质酸治疗相比，非格司亭治疗对阿谢曼综合征的效果更好。联合治疗未观察到有益效果。与透明质酸治疗相比，非格司亭治疗对阿谢曼综合征的疗效更好。联合治疗并未显示出超出单独使用非格司亭治疗所取得的额外益处。
